under 21 CFR 1240.63(a)(2)(ii) will be 480 hours (120 respondents x 4 hours per response = 480 hours).

Dated: February 10, 2004.

#### Jeffrey Shuren,

Assistant Commissioner for Policy. [FR Doc. 04-3485 Filed 2-18-04; 8:45 am] BILLING CODE 4160-01-S

### DEPARTMENT OF HEALTH AND **HUMAN SERVICES**

#### Food and Drug Administration

[Docket No. 2003N-0136]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Adoption of the FDA Food Code By Local, State, and Tribal Governments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Adoption of the FDA Food Code by Local State and Tribal Governments," has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

#### FOR FURTHER INFORMATION CONTACT:

Denver Presley, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1472.

SUPPLEMENTARY INFORMATION: In the Federal Register of October 2, 2003 (68 FR 56844), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0448. The approval expires on January 31, 2007. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ ohrms/dockets.

Dated: February 10, 2004.

#### Jeffrey Shuren,

Assistant Commissioner for Policy. [FR Doc. 04-3486 Filed 2-18-04; 8:45 am] BILLING CODE 4160-01-S

### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### Food and Drug Administration

[Docket No. 2003N-0360]

**Agency Information Collection** Activities: Submission for Office of Management and Budget Review: Comment Request; Information **Program on Clinical Trials for Serious** or Life-threatening Diseases: Maintaining of a Databank

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by March 22, 2004.

ADDRESSES: OMB is still experiencing significant delays in the regular mail, including first class and express mail, and messenger deliveries are not being accepted. To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: Fumie Yokota, Desk Officer for FDA, FAX: 202-395-6974.

#### FOR FURTHER INFORMATION CONTACT:

JonnaLynn P. Capezzuto, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659.

## SUPPLEMENTARY INFORMATION:

# I. Background

In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

## **Information Program on Clinical Trials** for Serious or Life-threatening Diseases: Maintaining a Databank —(OMB Control Number 0910-0459)—Extension

In the **Federal Register** of March 18, 2002 (65 FR 12022), FDA issued a guidance to industry on recommendations for investigational new drug application (IND) sponsors on submitting information about clinical trials for serious or life-threatening diseases to the Clinical Trials Data Bank developed by the National Library of Medicine, National Institutes of Health (NIH). This information is especially

important for patients and their families seeking opportunities to participate in clinical trials of new drug treatments for serious or life-threatening diseases. The guidance describes the following three collections of information: (1) Mandatory submissions, (2) voluntary submissions, and (3) certifications.

#### II. Mandatory Submissions

Section 113 of the Food and Drug Administration Modernization Act of 1997 (the Modernization Act) (Public Law 105-115) requires that sponsors shall submit information to the Clinical Trials Data Bank when the clinical trial: (1) Involves a treatment for a serious or life-threatening disease and (2) is intended to assess the effectiveness of the treatment. The final guidance discusses how sponsors can fulfill the requirements of section 113 of the Modernization Act. Specifically, sponsors should provide the following: (1) Information about clinical trials, both federally and privately funded, of experimental treatments (drugs, including biological products) for patients with serious or life-threatening diseases; (2) a description of the purpose of the experimental drug; (3) patient eligibility criteria; (4) the location of clinical trial sites; and (5) a point of contact for patients wanting to enroll in the trial. Senate 1789, "Best Pharmaceuticals for Children Act" (BPCA) (Public Law 107-109) established a new requirement for the Clinical Trials Data Bank mandated by section 113 of the Modernization Act. Information submitted to the data bank must now include "\* \* \* a description of whether, and through what procedure, the manufacturer or sponsor of the investigation of a new drug will respond to requests for protocol exception, with appropriate safeguards, for single-patient and expanded protocol use of the new drug, particularly in children." The final guidance will be updated to include a discussion of how sponsors can fulfill the BPCA requirements.

# **III. Voluntary Submissions**

Section 113 of the Modernization Act also specifies that sponsors may voluntarily submit information pertaining to results of clinical trials, including information on potential toxicities or adverse effects associated with the use or administration of the investigational treatment. Sponsors may also voluntarily submit studies that are not trials to test effectiveness, or not for serious or life-threatening diseases, to the Clinical Trials Data Bank.